Tonix Pharmaceuticals (NASDAQ:TNXP) Lowered to "Sell" Rating by Wall Street Zen

Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) was downgraded by research analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a research note issued on Friday.

Separately, Noble Financial reiterated an "outperform" rating and set a $70.00 target price on shares of Tonix Pharmaceuticals in a research note on Thursday, March 20th.

Tonix Pharmaceuticals Stock Down 5.3%

NASDAQ TNXP traded down $2.22 on Friday, reaching $39.80. The company had a trading volume of 1,571,151 shares, compared to its average volume of 891,944. The firm has a market capitalization of $291.54 million, a PE ratio of -0.01 and a beta of 1.63. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.33 and a quick ratio of 2.81. The firm has a 50-day moving average of $21.50 and a 200-day moving average of $22.14. Tonix Pharmaceuticals has a 1 year low of $6.76 and a 1 year high of $550.40.

Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) last released its earnings results on Monday, May 12th. The company reported ($2.84) EPS for the quarter, beating the consensus estimate of ($3.23) by $0.39. The company had revenue of $2.43 million during the quarter, compared to analysts' expectations of $2.55 million. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. On average, equities research analysts anticipate that Tonix Pharmaceuticals will post -1762.5 EPS for the current fiscal year.

Insider Activity at Tonix Pharmaceuticals

In other news, CEO Seth Lederman purchased 4,000 shares of Tonix Pharmaceuticals stock in a transaction dated Thursday, May 15th. The stock was bought at an average price of $21.55 per share, with a total value of $86,200.00. Following the completion of the acquisition, the chief executive officer now owns 4,005 shares in the company, valued at $86,307.75. The trade was a 80,000.00% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.03% of the company's stock.

Institutional Trading of Tonix Pharmaceuticals

A number of large investors have recently modified their holdings of TNXP. Commonwealth Equity Services LLC acquired a new stake in shares of Tonix Pharmaceuticals in the 4th quarter worth about $40,000. Two Sigma Investments LP acquired a new stake in shares of Tonix Pharmaceuticals in the 4th quarter worth about $66,000. PFG Investments LLC acquired a new stake in shares of Tonix Pharmaceuticals in the 4th quarter worth about $72,000. Northern Trust Corp acquired a new stake in shares of Tonix Pharmaceuticals in the 4th quarter worth about $162,000. Finally, IFP Advisors Inc acquired a new stake in shares of Tonix Pharmaceuticals in the 1st quarter worth about $179,000. Institutional investors and hedge funds own 82.26% of the company's stock.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.